Registration Dossier
Registration Dossier
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 310-060-2 | CAS number: 102110-59-8
Endpoint summary
Administrative data
Link to relevant study record(s)
Description of key information
Key value for chemical safety assessment
Additional information
Data usable for read-across purposes have been collected on the toxicokinetics of silica and silicates, which can be used for read-across purposes have been collected. There is no need to generate specific data related to Si/FeSi silicate.
Release tests in different synthetic biological fluids show that compared to the total amount of particles loaded, between 0.06 and 10% of the Si/FeSi silicate particles sized less than 0.05 mm were dissolved/released as silicon. Significantly higher quantities of silicon were dissolved/released in Gamble's fluid (<10%) than in gastric fluid (<2%) and in phosphate-buffered saline, artificial sweat, or artificial lysosomal fluid (<0.2%) after 168 hours of exposure.
After ingestion, amorphous silicon dioxide seems to have insignificant effects on tissue or urinary silicon levels. Since silicon in different forms is ubiquitous in the environment, various foods, drinking water and beverages contain silicon. Our normal dietary intake of silicon is between 20-50 mg Si/day, and the silicon in the diet seems to be in highly bioavailable form as shown as a high proportion of dietary silicon excreted in the urine. The differences in dietary intake are likely to explain the variability in urine levels of silicon among different individuals. Although in neutral solutions, elemental silicon and amorphous silicon dioxide is slowly dissolved, in acidic solutions the dissolution of silicon and amorphous silicon dioxide is significantly impaired. Thus, e. g., in the stomach, the release of silicon from silicon particles is likely to be low, which is likely to affect the absorption from the gastrointestinal tract.
After inhalation of synthetic amorphous silicon dioxide, the lung silicon content reaches a plateau level at which elimination equates with deposition. After the cessation of exposure amorphous silica is rapidly eliminated from the lung tissue.
No significant deposition into the lymph nodes has been seen in prolonged rat exposure during the first 40 days, but after 120 days, the retention was about 31% of total deposited (and 1.5 - 2% of theoretically deposited) silica. This suggests that the involvement of lymphatic elimination is not relevant in short exposure periods/lower body burdens.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
